A predictor of response in HER2+ breast cancer-at last!
| Errataetall: |
CommentOn: J Natl Cancer Inst. 2023 Mar 9;115(3):332-336. - PMID 36576009 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:115 |
|---|---|
| Enthalten in: |
Journal of the National Cancer Institute - 115(2023), 3 vom: 09. März, Seite 242-245 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Badve, Sunil S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Comment |
|---|
| Anmerkungen: |
Date Completed 10.03.2023 Date Revised 29.12.2023 published: Print CommentOn: J Natl Cancer Inst. 2023 Mar 9;115(3):332-336. - PMID 36576009 Citation Status MEDLINE |
|---|
| doi: |
10.1093/jnci/djac228 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350874166 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350874166 | ||
| 003 | DE-627 | ||
| 005 | 20240108135845.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jnci/djac228 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1242.xml |
| 035 | |a (DE-627)NLM350874166 | ||
| 035 | |a (NLM)36576003 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Badve, Sunil S |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A predictor of response in HER2+ breast cancer-at last! |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.03.2023 | ||
| 500 | |a Date Revised 29.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: J Natl Cancer Inst. 2023 Mar 9;115(3):332-336. - PMID 36576009 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Trastuzumab |2 NLM | |
| 650 | 7 | |a P188ANX8CK |2 NLM | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Gökmen-Polar, Yesim |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the National Cancer Institute |d 1945 |g 115(2023), 3 vom: 09. März, Seite 242-245 |w (DE-627)NLM000019747 |x 1460-2105 |7 nnns |
| 773 | 1 | 8 | |g volume:115 |g year:2023 |g number:3 |g day:09 |g month:03 |g pages:242-245 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/jnci/djac228 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 115 |j 2023 |e 3 |b 09 |c 03 |h 242-245 | ||